GO:0005104 fibroblast growth factor receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005104 (fibroblast growth factor receptor binding) is a molecular function defined as binding to a fibroblast growth factor receptor (FGFR) [QuickGO].
• FGF ligands, including FGF1, FGF2, FGF7, and FGF23, act as FGFR-binding proteins that trigger receptor dimerization and downstream signaling.
• FGFR binding is critical for phosphate sensing, skeletal development, and primary cilium regulation.
• Dysregulated FGFR binding underlies cancers, achondroplasia, and other developmental disorders, making it a major therapeutic target.
• FGFRs are proteolytically cleaved by metalloproteases, adding another layer of regulation to FGFR binding and signaling.
• Advanced methods such as DNA-assisted single-molecule super-resolution microscopy enable precise imaging of FGFR networks on the plasma membrane.
Description
Fibroblast growth factor receptor binding (GO:0005104) is a molecular function that describes the physical interaction between a protein and a fibroblast growth factor receptor (FGFR). This binding event is the first step in a cascade of signaling pathways that regulate cell proliferation, differentiation, survival, and migration. The FGFR family comprises four highly conserved receptor tyrosine kinases (FGFR1-4) that are activated upon binding by FGF ligands, leading to receptor dimerization, autophosphorylation, and downstream signal transduction. The importance of FGFR binding extends beyond basic cell biology; it is implicated in a wide range of physiological processes, including embryonic development, tissue repair, and metabolic homeostasis. In particular, FGF23 binding to FGFRs in the kidney regulates phosphate and vitamin D metabolism, highlighting the role of this interaction in systemic mineral balance. Moreover, mutations that alter FGFR binding affinity or specificity are linked to congenital disorders such as achondroplasia and craniosynostosis, as well as to various cancers. Understanding the molecular details of FGFR binding is therefore essential for both fundamental research and therapeutic development. This article provides a comprehensive overview of the GO:0005104 term, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and the experimental models and methods used to study it. By integrating authoritative QuickGO annotations with verified PubMed literature, we aim to equip researchers with a reliable resource for investigating FGFR binding in health and disease.
fibroblast growth factor receptor binding At A Glance
| GO ID | GO:0005104 |
|---|---|
| GO term | fibroblast growth factor receptor binding |
| Ontology | molecular_function |
| Synonym | FGFR binding, FGF receptor binding, FGFR ligand, fibroblast growth factor, fibroblast growth factor receptor ligand |
| Major function | Binding to fibroblast growth factor receptors (FGFRs), initiating receptor dimerization and downstream signaling. |
| Major ligands | FGF1, FGF2, FGF7, FGF23, and other FGF family members. |
| Associated receptors | FGFR1, FGFR2, FGFR3, FGFR4. |
| Disease relevance | Cancer, achondroplasia, hypophosphatemic rickets, and other developmental disorders. |
| Research methods | Surface plasmon resonance, co-immunoprecipitation, single-molecule imaging, CRISPR screens. |
What Is GO:0005104?
According to the Gene Ontology, GO:0005104 (fibroblast growth factor receptor binding) is defined as the binding to a fibroblast growth factor receptor (FGFR). This molecular function is attributed to proteins that physically interact with FGFRs, typically through specific structural domains. The binding event is non-covalent and reversible, and it is a prerequisite for FGFR activation and subsequent signal transduction. Synonyms for this term include FGFR binding, FGF receptor binding, FGFR ligand, fibroblast growth factor, and fibroblast growth factor receptor ligand. The term is classified under the molecular_function aspect of the Gene Ontology, indicating that it describes an activity rather than a biological process or cellular component. Proteins annotated with GO:0005104 include the FGF family of ligands (e.g., FGF1, FGF2, FGF7, FGF23) as well as other modulators that can bind FGFRs, such as certain viral proteins or synthetic binders. The binding specificity and affinity vary among different FGF ligands and FGFR isoforms, contributing to the diverse biological outcomes of FGFR signaling.
Why Is fibroblast growth factor receptor binding Important in Cell Biology?
Fibroblast growth factor receptor binding is a fundamental molecular event that governs a plethora of cellular processes, from embryonic development to tissue homeostasis and metabolism. It is the gateway to FGFR signaling, which controls cell proliferation, differentiation, survival, and migration. Dysregulation of this binding interaction is directly implicated in numerous human diseases, including cancers, where aberrant FGFR activation drives tumor growth and progression. In skeletal disorders such as achondroplasia, mutations in FGFR3 enhance ligand binding or receptor activation, leading to impaired bone growth. Additionally, FGF23-FGFR binding in the kidney is central to phosphate homeostasis, and its disruption causes hypophosphatemic rickets. The study of GO:0005104 therefore has broad implications for understanding both normal physiology and disease pathogenesis, and it is a prime target for therapeutic intervention.
• Initiates FGFR signaling, which regulates cell proliferation, differentiation, and survival.
• Critical for embryonic development, organogenesis, and tissue repair.
• Controls phosphate and vitamin D metabolism via FGF23-FGFR interaction in the kidney.
• Mutations in FGFRs that affect ligand binding cause skeletal dysplasias such as achondroplasia.
• Aberrant FGFR binding activity is oncogenic in multiple cancers, including breast, lung, and bladder.
• FGFR binding influences primary cilium length through interaction with intestinal cell kinase.
• FGFRs are subject to proteolytic cleavage by metalloproteases, modulating ligand binding and signaling.
• The term is a target for drug development, with several FGFR inhibitors in clinical trials.
• Understanding FGFR binding specificity can guide the design of selective therapeutic antibodies and small molecules.
• Advanced imaging techniques reveal dynamic FGFR networks on the plasma membrane, informing on binding kinetics.
What Happens During fibroblast growth factor receptor binding?
Ligand recognition and initial binding
In simple terms: FGF ligands recognize and attach to FGFRs on the cell surface.
The binding event begins when a fibroblast growth factor (FGF) ligand, such as FGF1 or FGF2, diffuses to the plasma membrane and encounters an FGFR. The ligand's binding site is complementary to the extracellular immunoglobulin-like domains of the receptor, allowing specific non-covalent interactions. This initial recognition is highly regulated and can be influenced by heparan sulfate proteoglycans, which act as co-receptors to stabilize the ligand-receptor complex. The affinity and specificity of this interaction determine which downstream pathways are activated.
Receptor dimerization and conformational change
In simple terms: Two FGFR molecules come together and change shape after ligand binding.
Upon ligand binding, two FGFR molecules are brought into close proximity, forming a dimer. This dimerization is essential for receptor activation because it allows the intracellular kinase domains to trans-phosphorylate each other. The conformational changes induced by ligand binding also expose phosphorylation sites that serve as docking sites for downstream signaling proteins. The dimerization process is dynamic and can be visualized using advanced imaging techniques such as DNA-assisted single-molecule super-resolution microscopy.
Activation of intracellular signaling cascades
In simple terms: The activated receptor sends signals inside the cell.
Once dimerized and phosphorylated, FGFRs recruit and activate several intracellular signaling pathways, including the RAS-MAPK, PI3K-AKT, and PLCγ pathways. These cascades lead to changes in gene expression, cell cycle progression, and cytoskeletal reorganization. The specificity of the downstream response is influenced by the particular FGF ligand and FGFR isoform involved, as well as by the cellular context.
Regulation by proteolytic cleavage and feedback
In simple terms: The receptor can be cut and the signal can be turned off.
FGFR signaling is tightly regulated by negative feedback mechanisms. One such mechanism involves proteolytic cleavage of the FGFR ectodomain by metalloproteases, which releases a soluble receptor fragment that can sequester ligands and dampen signaling. Additionally, ligand-induced receptor internalization and degradation contribute to signal termination. These regulatory processes ensure that FGFR binding does not lead to uncontrolled cell growth.
Crosstalk with primary cilium and other cellular structures
In simple terms: FGFR binding can affect the cell's antenna-like structure.
Recent studies have shown that FGFR signaling influences the length of the primary cilium through an interaction with intestinal cell kinase (ICK). This crosstalk highlights the integration of FGFR binding with other cellular machineries and its impact on processes such as mechanosensation and developmental signaling. The primary cilium acts as a signaling hub, and its regulation by FGFR binding adds another layer of complexity to the biological outcomes of this molecular function.
Key Genes Involved in GO:0005104 fibroblast growth factor receptor binding
The following genes encode proteins that either bind to FGFRs (ligands) or are FGFRs themselves, and they are central to the study of GO:0005104.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGF1 | Prototypical FGF ligand that binds all FGFR isoforms | Used as a model ligand to study FGFR binding affinity and specificity |
| FGF2 | Potent mitogen that binds FGFR1-4 | Widely studied in angiogenesis and cancer research |
| FGF7 | Keratinocyte growth factor (KGF) that specifically binds FGFR2b | Key regulator of epithelial cell proliferation and wound healing |
| FGF23 | Endocrine FGF that binds FGFR1c/α-Klotho complex | Central to phosphate homeostasis and kidney disease |
| FGFR1 | Receptor tyrosine kinase that binds multiple FGFs | Implicated in cancers, skeletal disorders, and Kallmann syndrome |
| FGFR2 | Receptor tyrosine kinase with epithelial-specific isoforms | Mutations cause craniosynostosis and cancers |
| FGFR3 | Receptor tyrosine kinase that inhibits bone growth | Mutations cause achondroplasia and related dwarfisms |
| FGFR4 | Receptor tyrosine kinase predominantly in endoderm | Target in hepatocellular carcinoma and rhabdomyosarcoma |
| KL | Klotho, a co-receptor for FGF23-FGFR binding | Essential for FGF23 signaling in phosphate regulation |
| HS6ST1 | Heparan sulfate 6-O-sulfotransferase | Modifies heparan sulfate to modulate FGF-FGFR binding |
| NDST1 | N-deacetylase/N-sulfotransferase | Influences heparan sulfate structure and FGF signaling |
| ICK | Intestinal cell kinase | Interacts with FGFR to regulate primary cilium length |
| ADAM17 | Metalloprotease that cleaves FGFR ectodomain | Regulates FGFR availability and signaling |
| MMP2 | Matrix metalloproteinase-2 | Can cleave FGFRs and modulate binding |
| FGF8 | Ligand involved in embryonic development | Critical for brain and limb development |
| FGF10 | Ligand that binds FGFR2b | Essential for lung and limb morphogenesis |
| FGF18 | Ligand that binds FGFR3c | Regulates bone growth and cartilage development |
| FGF19 | Endocrine FGF that binds FGFR4 | Regulates bile acid and glucose metabolism |
How Is fibroblast growth factor receptor binding Regulated?
The binding of FGF ligands to FGFRs is regulated at multiple levels. Extracellularly, heparan sulfate proteoglycans (HSPGs) act as co-receptors that facilitate and stabilize the ligand-receptor complex, and their sulfation patterns influence binding specificity. Proteolytic cleavage of FGFRs by metalloproteases such as ADAM17 and MMP2 can release soluble ectodomains that compete for ligand binding, thereby modulating signaling. Intracellularly, feedback mechanisms involving Sprouty proteins, SEF, and MAPK phosphatases attenuate downstream signaling following FGFR activation. Additionally, receptor trafficking and ubiquitination control the duration and intensity of signaling. These regulatory layers ensure that FGFR binding is tightly controlled in space and time, preventing aberrant activation that could lead to disease.
fibroblast growth factor receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGFR3 | Achondroplasia (gain-of-function mutations enhance ligand binding) | Knock-in mouse models with FGFR3 G380R mutation |
| FGFR1 | Kallmann syndrome and craniosynostosis | Patient-derived iPSCs with FGFR1 mutations |
| FGF23 | Hypophosphatemic rickets (excess FGF23 activity) | Fgf23 transgenic mice or KL knockout models |
| FGFR2 | Crouzon syndrome and cancers | CRISPR knock-in of FGFR2 mutations in cell lines |
| FGFR4 | Hepatocellular carcinoma | FGFR4 knockout or overexpression in liver cancer cell lines |
FGFR binding in cancer
Dysregulated FGFR binding and signaling are oncogenic drivers in many cancers. Amplifications, mutations, and translocations in FGFR genes can lead to ligand-independent activation or hypersensitivity to FGF ligands, promoting tumor cell proliferation, survival, and angiogenesis. For example, FGFR1 amplification is common in lung squamous cell carcinoma, and FGFR3 mutations are frequent in bladder cancer. Targeting the FGFR binding interface with monoclonal antibodies or small molecule inhibitors has shown clinical promise.
FGFR binding in skeletal disorders
Achondroplasia, the most common form of dwarfism, is caused by gain-of-function mutations in FGFR3 that enhance ligand binding or receptor activation, leading to excessive inhibition of chondrocyte proliferation. Similar mutations in FGFR1 and FGFR2 cause craniosynostosis syndromes. Understanding how these mutations affect FGFR binding affinity and specificity is crucial for developing targeted therapies.
FGFR binding in metabolic and kidney diseases
FGF23 binding to FGFR1c in the presence of the co-receptor α-Klotho is essential for phosphate homeostasis. Impaired FGF23-FGFR binding leads to hypophosphatemic rickets and hyperphosphatemia, while excess FGF23 causes chronic kidney disease-mineral and bone disorder. The molecular details of this binding interaction are therefore of great clinical interest.
From fibroblast growth factor receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene product bind to FGFR? | In vitro binding assays (SPR, ELISA) with recombinant proteins |
| What is the effect of a specific FGFR mutation on ligand binding? | Point-mutation knock-in cell lines using CRISPR |
| How does loss of an FGF ligand affect downstream signaling? | Knockout cell lines or animal models |
| Can we visualize FGFR binding dynamics on live cells? | Tagged knock-in of FGFR with fluorescent proteins and super-resolution microscopy |
| What is the role of FGFR binding in tumor growth? | Xenograft models with FGFR-overexpressing cancer cells |
| How does proteolytic cleavage regulate FGFR binding? | Overexpression of metalloproteases or knockout of ADAM17/MMP2 |
How to Study the fibroblast growth factor receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics (kon, koff, Kd) | Characterizing FGF-FGFR interactions |
| Co-immunoprecipitation | Physical interaction between proteins | Confirming FGFR binding in cell lysates |
| Single-molecule super-resolution microscopy | Spatial distribution and clustering of FGFRs | Imaging FGFR networks on plasma membrane |
| Western blot | Phosphorylation status of FGFR and downstream targets | Assessing FGFR activation |
| Luciferase reporter assay | Transcriptional activity downstream of FGFR | Screening for modulators of FGFR signaling |
| CRISPR knockout screen | Genes required for FGFR binding or signaling | Identifying novel regulators |
| Proteolytic cleavage assay | Release of soluble FGFR ectodomain | Studying metalloprotease-mediated regulation |
| Primary cilium length measurement | Cilium length changes upon FGFR binding | Investigating FGFR-ICK crosstalk |
Biochemical binding assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are used to measure the affinity and kinetics of FGF-FGFR binding. These methods provide quantitative data on dissociation constants (Kd) and can be used to compare wild-type and mutant proteins.
Cell-based signaling assays
Luciferase reporter assays, Western blotting for phosphorylated FGFR and downstream effectors (e.g., ERK, AKT), and proliferation assays are commonly used to assess the functional consequences of FGFR binding in cell culture models.
Advanced imaging techniques
DNA-assisted single-molecule super-resolution microscopy allows visualization of individual FGFR molecules on the plasma membrane, revealing clustering and binding dynamics in unprecedented detail. This technique is particularly useful for studying how ligand binding induces receptor oligomerization.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that modulate FGFR binding and signaling. Such screens have uncovered novel regulators of FGF signaling and potential therapeutic targets.
How CRISPR Can Be Used to Study GO:0005104 fibroblast growth factor receptor binding
Knockout
CRISPR knockout of FGF ligands or FGFRs can abolish specific binding interactions, allowing researchers to study the loss-of-function phenotypes. For example, knocking out FGFR3 in chondrocytes can reverse the effects of achondroplasia mutations. Knockout models are also valuable for validating drug targets.
Point Mutation
Introducing point mutations that alter the binding interface of FGF or FGFR can dissect the contribution of specific residues to binding affinity and specificity. This approach is particularly useful for modeling human disease mutations, such as the FGFR3 G380R mutation in achondroplasia.
Knock-in
Knock-in of tagged FGFRs (e.g., GFP or HaloTag) enables real-time imaging of receptor trafficking and binding dynamics. Knock-in of disease-associated mutations into cell lines or animal models provides physiologically relevant systems for studying FGFR binding in disease.
Overexpression
Overexpression of FGF ligands or FGFRs using CRISPR activation (CRISPRa) or lentiviral vectors can amplify signaling and reveal gain-of-function phenotypes. This is useful for studying oncogenic roles of FGFR binding and for screening inhibitors.
How EDITGENE Supports fibroblast growth factor receptor binding Research
Researchers studying fibroblast growth factor receptor binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. This requires precise genetic manipulation, which can be achieved through CRISPR-based knockout, point mutation, knock-in, or overexpression models. EDITGENE provides a comprehensive suite of services to generate such models, enabling rigorous investigation of FGFR binding biology.
Contact EDITGENE today to design your custom CRISPR model for fibroblast growth factor receptor binding research.
Frequently Asked Questions About fibroblast growth factor receptor binding
What is fibroblast growth factor receptor binding?
Fibroblast growth factor receptor binding (GO:0005104) is a molecular function defined as the binding to a fibroblast growth factor receptor (FGFR). It is the first step in FGFR signaling and is mediated by FGF ligands such as FGF1, FGF2, and FGF23.
What genes are involved in fibroblast growth factor receptor binding?
Key genes include FGF ligands (FGF1, FGF2, FGF7, FGF23) and FGFR receptors (FGFR1-4). Other modulators include KL (Klotho), heparan sulfate proteoglycans, and metalloproteases like ADAM17.
What diseases are associated with fibroblast growth factor receptor binding?
Dysregulated FGFR binding is linked to cancers (e.g., lung, bladder), skeletal disorders (achondroplasia, craniosynostosis), and metabolic diseases such as hypophosphatemic rickets.
How is fibroblast growth factor receptor binding studied?
Common methods include surface plasmon resonance, co-immunoprecipitation, Western blotting for phosphorylated FGFR, and advanced imaging like single-molecule super-resolution microscopy.
What is the role of FGF23 in fibroblast growth factor receptor binding?
FGF23 binds to FGFR1c in complex with the co-receptor α-Klotho to regulate phosphate homeostasis. Impaired binding leads to hypophosphatemic rickets.
Can CRISPR be used to study fibroblast growth factor receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the molecular details and functional consequences of FGFR binding.
What are the synonyms for GO:0005104?
Synonyms include FGFR binding, FGF receptor binding, FGFR ligand, fibroblast growth factor, and fibroblast growth factor receptor ligand [QuickGO].
Which FGFR is most commonly mutated in achondroplasia?
FGFR3 is the primary gene mutated in achondroplasia, with mutations that enhance ligand binding or receptor activation.
How does proteolytic cleavage affect FGFR binding?
Metalloproteases such as ADAM17 and MMP2 cleave the FGFR ectodomain, releasing soluble fragments that can sequester ligands and modulate signaling.
What is the connection between FGFR binding and primary cilia?
FGFR signaling influences primary cilium length through an interaction with intestinal cell kinase (ICK), linking FGFR binding to ciliary biology.
Conclusion
Fibroblast growth factor receptor binding (GO:0005104) is a pivotal molecular function that initiates a wide array of signaling cascades controlling cell growth, differentiation, and metabolism. Its dysregulation is implicated in numerous human diseases, from cancer to skeletal dysplasias and metabolic disorders. Understanding the structural and functional details of this binding event is essential for developing targeted therapies. The integration of CRISPR-based genetic models, advanced imaging, and biochemical assays continues to unravel the complexities of FGFR binding. EDITGENE's comprehensive services in knockout, point mutation, knock-in, overexpression, and CRISPR screening empower researchers to explore this critical interaction with precision and depth.
References
- 1. Takashi Y et al.. 2020. Fibroblast growth factor receptor as a potential candidate for phosphate sensing.. Curr Opin Nephrol Hypertens 29(4):446-452 PMID: 32427693
- 2. Kumar SB et al.. 2013. Fibroblast growth factor receptor inhibitors.. Curr Pharm Des 19(4):687-701 PMID: 23016864
- 3. Schröder MS et al.. 2021. Imaging the fibroblast growth factor receptor network on the plasma membrane with DNA-assisted single-molecule super-resolution microscopy.. Methods 193:38-45 PMID: 32389748
- 4. Aviezer D et al.. 2003. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.. Curr Drug Targets 4(5):353-65 PMID: 12816345
- 5. Kunova Bosakova M et al.. 2019. Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinase.. Proc Natl Acad Sci U S A 116(10):4316-4325 PMID: 30782830
- 6. Agrawal S et al.. 2021. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.. Curr Drug Targets 22(2):214-240 PMID: 33045958
- 7. Rubin JS et al.. 1995. Keratinocyte growth factor.. Cell Biol Int 19(5):399-411 PMID: 7640656
- 8. Dixit G et al.. 2021. Members of the Fibroblast Growth Factor Receptor Superfamily Are Proteolytically Cleaved by Two Differently Activated Metalloproteases.. Int J Mol Sci 22(6) PMID: 33804608
